UCB Adds Cradle’s AI Platform to Antibody Discovery Projects

On November 4, 2026, UCB partnered with Cradle to integrate Cradle's AI-driven protein design platform into UCB's antibody discovery efforts, enhancing hit generation through lead optimization. The platform uses experimental feedback to iteratively improve antibody candidates across multiple properties, aiming to accelerate development of high-quality therapeutics.